José Peña Guerrero-rekin lankidetzan egindako argitalpenak (6)

2022

  1. Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis

    Pharmaceutics, Vol. 14, Núm. 11

  2. The BRCT Domain from the Homologue of the Oncogene PES1 in Leishmania major (LmjPES) Promotes Malignancy and Drug Resistance in Mammalian Cells

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

2021

  1. In leishmania major, the homolog of the oncogene pes1 may play a critical role in parasite infectivity

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

2020

  1. LmjF.22.0810 from leishmania major modulates the TH2-type immune response and is involved in leishmaniasis outcome

    Biomedicines, Vol. 8, Núm. 11, pp. 1-17

2019

  1. The novel serine/threonine protein kinase lmjf.22.0810 from Leishmania major may be involved in the resistance to drugs such as paromomycin

    Biomolecules, Vol. 9, Núm. 11

2017

  1. Construction of Two mCherry Plasmids (pXG-mCherry) for Transgenic Leishmania: Valuable Tools for Future Molecular Analysis

    Journal of Parasitology Research, Vol. 2017